Worldwide live births following the transfer of chromosomally “Abnormal” embryos after PGT/A: results of a worldwide web-based survey
Tóm tắt
Preimplantation genetic testing for aneuploidy (PGT-A) has become increasingly controversial since normal euploid births have been reported following transfer of embryos diagnosed as “abnormal.” There is an increasing trend in transferring “abnormal” embryos; but it is still unknown how many IVF centers transfer “abnormal” embryos and with what efficiency. We performed a worldwide web-survey of IVF centers to elucidate PGT-A related practice patterns including transfer of human embryos found “abnormal” by PGT-A. Participating centers reflected in vitro fertilization (IVF) cycles in the USA, Canada, Europe, Asia, South America, and Africa. One hundred fifty-one IVF centers completed the survey; 125 (83%) reported utilization of PGT-A. Europe had the highest utilization (32.3%), followed by the USA and Canada combined at 29.1%. The leading indications for PGT-A were advanced maternal age (77%), followed by recurrent implantation failure (70%), unexplained pregnancy loss (65%), and sex determination (25%); 14% of respondents used PGT-A for all of their IVF cycles; 20% of IVF units reported transfers of chromosomally “abnormal” embryos, and 56% of these took place in the USA, followed by Asia in 20%. Remarkably, 106 (49.3%) cycles resulted in ongoing pregnancies (n = 50) or live births (n = 56). Miscarriages were rare (n = 20; 9.3%). The transfers of “abnormal” embryos by PGT-A offered robust pregnancy and live birth chances with low miscarriage rates. These data further strengthen the argument that PGT-A cannot reliably determine which embryos should or should not be transferred and leads to disposal of many normal embryos with excellent pregnancy potential.
Tài liệu tham khảo
Weissman A, Shoham G, Shoham Z, Fishel S, Leong M, Yaron Y. Chromosomal mosaicism detected during preimplantation genetic screening: results of a worldwide Web-based survey. Fertil Steril. 2017;107:1092–7.
Position statement on chromosome mosaicism and preimplantation aneuploidy testing at the blastocyst stage [Internet]. 2016 [cited 2019 Apr 26]. Available from: http://www.pgdis.org/docs/newsletter_071816.html. Accessed 3 Jan 2019
Gleicher N, Vidali A, Braverman J, Kushnir VA, Albertini DF, Barad DH. Further evidence against use of PGS in poor prognosis patients: report of normal births after transfer of embryos reported as aneuploid. Fertil Steril. 2015;104:e59.
Greco E, Minasi MG, Fiorentino F. Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts. N Engl J Med. 2015;373:2089–90.
Gleicher N, Orvieto R. Is the hypothesis of preimplantation genetic screening (PGS) still supportable? J Ovarian Res. 2017;10(1):21–8. Available from: https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-017-0318-3. Accessed 26 Apr 2019
Munné S, Blazek J, Large M, Martinez-Ortiz PA, Nisson H, Liu E, et al. Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. Fertil Steril. 2017;108:62–71.e8.
Kushnir VA, Darmon SK, Barad DH, Gleicher N. Degree of mosaicism in trophectoderm does not predict pregnancy potential: a corrected analysis of pregnancy outcomes following transfer of mosaic embryos. Reprod Biol Endocrinol. 2018;16:6.
Paulson RJ. Preimplantation genetic screening: what is the clinical efficiency? Fertil Steril. 2017;108:228–30.
Gleicher N, Vidali A, Braverman J, Kushnir VA, Barad DH, Hudson C, et al. Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos. Reprod Biol Endocrinol. 2016;14:54.
Morales R, Lledó B, Ortiz JA, Ten J, Lláce J, Bernabeu R. Embryos showing mosaicism in trophectoderm cells can achieve good pregnancy rates. Hum Reprod. 2016;1:0–030.
Lledo' B, Morales R, Ortiz JA, Blanca H, Ten J, Llacer J, Bernabeu R. Implantation potential of mosaic embryos. Syst Biol Reprod Med 2017;63(3):206–8.
Spinella F, Fiorentino F, Biricik A, Bono S, Ruberti A, Cotroneo E, et al. Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. Fertil Steril. 2018;109:77–83.
Zore T, Kroener LL, Wang C, Liu L, Buyalos R, Hubert G, Shamonki M. Fertil Steril. 2019;111(1):69–76.
Vaisbuch E, Leong M, Shoham Z. RBMO. 2012;25(2):139–45.
Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;16:121.
Neal SA, Morin SJ, Franasiak JM, Goodman LR, Juneau CR, Forman EJ, et al. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage. Fertil Steril. 2018;110:896–904.
Murugappan G, Shahine LK, Perfetto CO, Hickok LR, Lathi RB. Hum Reprod. 2016;31(8):1668–74.
Chang Y, Li J, Li X, Liu H, Liang X. Egg quality and pregnancy outcome in young infertile women with diminished ovarian reserve. Med Sci Monit. 2018;24:7279–84.
Murphy LA, Seidler EA, Vaughan DA, Resetkova N, Penzias AS, Toth TL, et al. To test or not to test? A framework for counselling patients on preimplantation genetic testing for aneuploidy (PGT-A). Hum Reprod. 2019;34:268–75.
Santiago M. Forty years of IVF - evolution of preimplantation genetic screening. Fertil Steril. 2018;110:185–324 e5.
Gleicher N, Kushnir VA, Barad DH. How PGS/PGT-A laboratories succeeded in losing all credibility. Reprod BioMed Online. 2018;37:242–5.